FBS Superior: Standardized serum

In order to even the usual variations of the biological characteristics of FbS batches, Gentaur offers with FbS Superior a standardized quality serum. due to the addition of selected synthetic supplements, a continuous high level of quality is guaranteed. Manage outine cell culture in the future without any need to test FbS batches, and use the FbS Superior that provides constant quality and excellent growth-enhancing characteristics.

• once tested, FbS provides a balanced constant growth profile
• save further testing in the future
• the costs for FbS Superior are the same compared to usual eU-approved FbS
• FbS Superior is always available
• virus tested
• mycoplasma-free

Cat. Number: S 0615

Download Datasheet

Download Safety Datasheet

or Click Here

Image of an HIV-infected H9 T cell, colorized in blue, turqoise, and yellow set against a dark background.

Braasch Biotech announced that they have received the first patent for anti-somatostatin vaccine for the treatment of obesity in dogs and cats. This is the first patent granted for the treatment of obesity by the vaccine.

Happily curious prevalence of obesity among farmers move in parallel with their pets. In the U.S., 52.5% of dogs and 58.3% of the cats are overweight. U.S. veterinarians warn that 80 million dogs at risk of arthritis, diabetes, hypertension and a number of cancers.

Just like in humans, obesity in pets reached epidemic dimensions. Once reached the pathological condition, the animal needs the intervention of the holder in order to revert to a healthy weight. The vaccine is one of the few alternatives other than additional walks in the park. Yet its registration in the European Union, Brazil, Mexico, Canada, the USA and Japan.

Braasch Biotech have an extensive portfolio of anti-somatostatin products for the treatment of a number of metabolic diseases.

Catalog number : YK090-SP
Quantity: 96well

Product Overview:
Glucagon is the most important counter-regulatory hormone to insulin in blood glucose homeostasis. It elevates blood glucose levels by stimulating gluconeogenesis and glycogenolysis while inhibiting glycogenesis and gylcolysis in the liver. This hormone is extremely important in studying therapeutic targets for diabetes, particularly Type I.
Background Information:
This assay is a chemiluminescent sandwich ELISA and is based on the capture of glucagon molecules in the sample, after extraction and reconstitution. This kit specifically measures intact glucagon, which is unique to many commercially available assays.
Usage Statement:
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Linearity of Dilution:
Contact Technical Service for this information
Sensitivity:
.003 ng/mL

Accuracy:
101%
Detection Methods:
Chemiluminescence
Cross Reactivity:
Refer to kit protocol for details
Product Name:
Glucagon ELISA Kit, Chemiluminescent
Standard Curve Range:
0.02 - 2 ng/mL
Specificity:
Glucagon (Human, Mouse, Rat and Porcine) 100%
Oxyntomodulin (Human, Mouse and Rat) <5%
Glucagon (1-18) 0%
Glucagon 19-29 (mini Glucagon) 0%
Analytes Available:
Glucagon

 Price: 741 EUR

FDA has approved two drugs to GlaxoSmithKline for the treatment of advanced melanoma - the most aggressive skin cancer patients with specific genetic mutations. Regulatory approvals, and diagnostic test for demonstrating these mutations.
 
The drugs are approved for administration separately, once in two separate clinical trials, they showed delayed tumor growth.

After decades of virtually no progress in the fight against advanced melanoma, two new drugs celebrated turn in favor of medicine. Over the past two years, FDA has approved a total of 4 new drugs this indication.
 
Each year in the U.S. from melanoma ill about 75 000 people. The mortality rate is around 9,000 to 10,000 per year.
 
Forecast sales for each of the two new drugs are about 350 million dollars a year.

According to a study published in the journal The Lancet, confirmed the first cases of resistance in avian influenza virus strain N7N9 to Tamiflu and related drugs. The study, conducted by the team of Dr. Yang from the Shanghai Center for Public Health, has been described as one of the finest virology research done so far.

The team examined 14 people infected with the strain N7N9, and track viral load (the content of virus in the blood) in the course of treatment. All study participants developed pneumonia. Seven of them require assisted ventilation, and three others - from extracorporeal membrane oxygenation of the blood - a procedure in which blood is oxygenated using an external device, as the lungs do not function properly. Two of these patients die after the infection.

Researchers found that 11 patients Tamiflu lowers viral load, while most seriously ill he continued to grow, even during treatment. According to the team, this means that the strain acquired resistance to Tamiflu, and maybe even the entire class of drugs called neuraminidase inhibitors.

Assumption was later confirmed by genetic studies of viruses that detect mutations characteristic of neuraminidase inhibitor-resistant strains. This is the first study linking these mutations with resistance in strains N7N9. According to the authors, in all cases, early treatment provides the best chance of recovery.
 
Earlier this month, reports surfaced that N7N9 strain can spread from person to person. According to the World Health Organization is currently developing a vaccine that provides immunity against the agent.

More Sharp! High Resolution! More Convenience!

AccuLadder 100 bp DNA size marker was designed to determine the size of double stranded DNA fragments from 100 to 2,000 bp. AccuLadder is shaper and brighter than our standard 100bp ladder The AccuLadder 100 bp DNA size marker consists of 13 double stranded molecular weight markers ranging in sizes from 100 to 1,000 bp in 100 bp increments, and additional fragments of 1,200, 1,600, 2,000 bp. The 500, 1,000 and 2,000 bp bands are two times brighter for easy identification.

Note:
The DNA ladder can be applied directly onto an agarose gel.
There is no need to heat before loading. Repeated freezing and thawing should be avoided.

Features and Benefits

Specifications

Concentration: 54 ng/μl
Recommended loading: 4.0~5.0 μl / 5 mm lane width
Typical Number of lanes: 126~157 (5 mm lane width)
Size range (bp): 100 - 2,000
Number of bands: 13
Supplied in: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 2.5% Ficoll, 0.005% Bromphenol Blue, 0.005% Xylene Cyanol
Storage: -20°C

2.0% TBE agarose gel stained with Ethidium Bromide.

Nuclease Activity Test

AccuPower® ProFi Taq PCR PreMix for high efficiency and amplification of long range PCR.

AccuPower® ProFi Taq PCR PreMix is a convenient lyophilized PCR master mix containing ProFi Taq DNA polymerase, reaction buffer, dNTPs, tracking dye, and a patented stabilizer. ProFi Taq DNA polymerase in the premix is a unique recombinant Taq DNA polymerase that offers enhanced amplification efficiency and higher fidelity for PCR. AccuPower® ProFi Taq PCR PreMix is applicable to any template DNA, and especially effective in amplifying large genomic DNA fragments around 20 kb. AccuPower® ProFi Taq PCR PreMix provides accurate long-range amplification of standard and amplification of low-copy target, and is highly suitable for all PCR applications.

Features and Benefits

Specifications

5' to 3' exonuclease: Yes
3' to 5' exonuclease: Yes
3' – A Overhang: Yes
PCR product size: ~ 30kb

Application

- Primer extension
- long-range amplification from genomic DNA
- High amplification efficiency
- Excellent performance on difficult templates
- Amplification of low-copy targets
- High yield and high sensitivity PCR

Experimental data

Figure 1. Comparison of PCR amplification efficiency between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5min, 30 cycles of 95°C for 20 sec, 55°C for 20 sec and 72°C for 30 sec. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol.
Target : human insulin receptor gene.
Lane M : 100 bp DNA Ladder(Gentaur, Cat. No. D-1030)
Lane 1 : 10 ng of human genomic DNA
Lane 2 : 1 ng of human genomic DNA
Lane 3 : 100 pg of human genomic DNA
Lane 4 : 10 pg of human genomic DNA

Figure 2. Comparison of PCR amplification efficiency between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

cDNA synthesized from 10-fold serial-diluted human total RNA from 10 ng to 10 pg using AccuPower® RocketScript™ Cycle RT PreMix. (Gentaur, Cat. No K-2201) wase used as a template for PCR amplification. The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5min, 33 cycles of 95°C for 20 sec, 55°C for 20 sec and 72°C for 30 sec. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol.
Target : human GAPDH gene.
Lane M : 100 bp DNA Ladder(Gentaur, Cat. No. D-1030)
Lane 1 : 10 ng of human total cDNA
Lane 2 : 1 ng of human total cDNA
Lane 3 : 100 pg of human total cDNA
Lane 4 : 10 pg of human total cDNA

Figure 3. Comparison of PCR amplification of long targets between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5 min, 30 cycles of 95°C for 20 sec, 65°C for 20 sec and 68°C for 4 min. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol.
Lane M1 : Lambda/Hind III marker (Gentaur, Cat. No. D-1050)
Lane M2 : 1 kb DNA Ladder (Gentaur, Cat. No. D-1040)
Lane 1 : 2 kb fragment (human tumor protein p53 gene)
Lane 2 : 3 kb fragment (human tumor protein p53 gene)
Lane 3 : 4.5kb fragment (human DNA cross-link repair 1A gene)
Lane 4 : 8 kb fragment (human hemoglobin epsilon 1 gene)

Figure 4. Comparison of PCR amplification of long targets between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5 min, 32 cycles of 95°C for 20 sec and 68°C for 15 min. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol. Human genomic DNA was used as a template for PCR amplification.
Lane M1 : Lambda/Hind III marker (Gentaur, Cat. No. D-1050)
Lane M2 : 1 kb DNA Ladder (Gentaur, Cat. No. D-1040)
Lane 1 : 11 kb fragment
Lane 2 : 13.5 kb fragment
Lane 3 : 17.6 kb fragment
Lane 4 : 21.4 kb fragment

Figure 5. Comparison of PCR amplification of long targets between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5 min, 32 cycles of 95°C for 20 sec, 65°C for40 sec, and 68°C for 20 min. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol. Lambda DNA was used as a template for PCR amplification.
Lane M1 : Lambda/Hind III marker (Gentaur, Cat. No. D-1050)
Lane M2 : 1 kb DNA Ladder (Gentaur, Cat. No. D-1040)
Lane 1 : 15 kb fragment
Lane 2 : 20 kb fragment
Lane 3 : 25 kb fragment
Lane 4 : 30 kb fragment

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe cases of the disease, the immune system makes a unique subset of antibodies that have a disease-promoting role.

Reporting in the journal Science Translational Medicine online May 22, the Johns Hopkins team describes how it found the novel antibodies to peptidylarginine deiminase 4, or PAD4, in blood samples from people with aggressive inflammation and connective tissue damage.

Researchers say the presence of so-called PAD3/PAD4 cross-reactive autoantibodies could serve as the basis for the first antibody-specific diagnostic test to distinguish those with severe rheumatoid arthritis from those with less aggressive forms of the disease.
"Identifying early on a subset of patients with severe rheumatoid arthritis could benefit their health, as these patients could start aggressive drug therapy immediately and find the most effective treatment option," says senior study investigator Antony Rosen, M.D. Rosen, director of rheumatology and the Mary Betty Stevens Professor at the Johns Hopkins University School of Medicine, says that a third, or 1 million of the more than 3 million Americans -- mostly women -- estimated to have rheumatoid arthritis have an aggressive form of the disease.
In the study, the antibodies were present -- in 18 percent of 44 fluid samples from one research collection and in 12 percent of another collection of 194 -- but only in people with severe cases of rheumatoid arthritis. Past research shows that those with the most aggressive disease are less likely to respond to anti-inflammatory treatments with steroids and other drugs.
An examination of patients' medical records revealed that 80 percent of patients with the antibody saw their disease worsen over the previous year, while only 53 percent without the antibody showed disease progression. In comparing average scores of disease-damaged joints, researchers found that those with the antibody had an average deterioration in joints and bones by a score of 49. Those without the antibody had an average degradation in their score of 7.5, indicating much milder disease.
In a related finding, the Johns Hopkins team also uncovered how the PAD3/PAD4 cross-reactive auto-antibodies might contribute to more severe, erosive disease in rheumatoid arthritis. The team performed a series of experiments to gauge the antibodies' effects on PAD4 in response to varying cell levels of calcium, on which PAD enzymes depend.
Lab experiments showed that the antibodies greatly increase PAD4 enzyme function at the low levels of calcium normally present in human cells. Results showed that PAD4 activity was 500 times greater in the presence of antibodies than when they were absent. Tests of the antibody and enzymes' chemical structures later showed that the antibodies bind to PAD4 in the same region as calcium, suggesting to researchers that the antibodies might be substituting for calcium in activating the enzyme.
According to Rosen, the series of experiments, which took two years to complete, represents the first evidence of an antibody having a direct role in generating the targets of the immune response, or auto-antigens, in rheumatoid arthritis.
"Our results suggest that drugs inhibiting the PAD4 enzyme may have real benefit in patients with severe rheumatoid arthritis and represent an important field of study for investigating new and alternative treatments," says lead study investigator and biologist Erika Darrah, Ph.D.
Darrah says the team next plans long-term monitoring of arthritis sufferers to find out when the antibody first appears in the blood, and when intervention may have maximum impact in preventing or stalling disease progression. The team also plans further experiments to see if the antibody is taking control of the chemical pathways normally used by other cell proteins to control PAD4 sensitivity to calcium.
Funding support for this study was provided by the National Institutes of Health, and corresponding grant number T32-AR048522; the American College of Rheumatology; the Donald B. and Dorothy L. Stabler Foundation; and Sibley Memorial Hospital.
In addition to Rosen and Darrah, other Johns Hopkins researchers involved in this study were Jon Giles, M.D.; Michelle Ols, Ph.D.; and Felipe Andrade, M.D., Ph.D. Additional research assistance was provided by enzymologist Herbert Bull, Ph.D.

New Stem Cells on the Block

Researchers have for the first time produced human embryonic stem cells (hESCs) using somatic nuclear transfer (SCNT), a method in which the nucleus of a donor cell—in this case a skin cell or fibroblast—is transferred to an egg cell whose own nucleus has been removed.

The work, published in Cell, opens up the possibility of an alternative source of patient-specific stem cells to help scientists understand disease and develop personalized cell-based therapies. What’s more, hESCs produced via nuclear transfer (NT-hESCs) may not have the genetic and epigenetic abnormalities found in induced pluripotent stem cells (iPSCs), made by adding key genes to reprogram adult cells….. Continue reading HERE

GENTAUR offers you a way to homogenize, disrupt, or lyse up to 24 tissue or cell culture samples at a time + keeping your samples cool.

*The Bullet Blender Familiy

BB24-AU Bullet Blender GOLD  NEW! - 5873 EUR

BB50-DX-CE Bullet Blender 50-DX homogenizer, CE certified, air cooling and noise insulation-3830 EUR

BBX24-CE Bullet Blender homogenizer, CE certified, for up to 24 tissue_cell samples - 2500 EUR

*PAG-Electrophoresis? GENTAUR offers you the full equipment!

AE-6500 Dual Mini Slab & MANY MORE HERE

*WE can provide you with the unique ready to use kits with special cell cultures.

CacoGoblet 24 KRECE-CCG01 - 1295 EUR

CacoGoblet 96 KRECE-CCG50 - 2255 EUR

CacoGoblet, allows in vitro intestinal absorption evaluation of drug targets in a barrier physiologically closer to the intestinal epithlium.

CacoReady 24 Express KRECE-CCR10 - 1355 EUR

CacoReady 96 KRECE-CCR50 - 1995 EUR

CacoReady™ Allows in vitro intestinal absorption evaluation of drug targets.

IsoCypTox Individual (3A4, 2E1, 1A2, 2A6) KRECE-ICT51, -ICT52, -ICT53, -ICT54 - 945 EUR

IsoCyp-Tox allows in vitro detection and screening of biotransformation-mediated toxicity of lead and drug targets in just one single experiment.